EZ-ONE 1.5mg price in UAE

Overview

Welcome to Dwaey, specifically on EZ-ONE 1.5mg Tablet page.
This medicine contains an important and useful components, as it consists of Levonorgestrel.
EZ-ONE 1.5mg is available in the market in concentration 1.5mg/tablet and in the form of Tablet.

NAARI B.V. is the producer of EZ-ONE 1.5mg and it is imported from NETHERLANDS, The most popular alternatives of EZ-ONE 1.5mg are listed downward .

Mode Of Action

Levonorgestrel, a nortestosterone derivative, is an active isomer of norgestrel. It is a potent inhibitor of ovulation and has androgenic activity.

Indication

Contraception
Emergency contraception
Menopausal hormone replacement therapy
Menorrhagia

Precaution

Sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, CV or renal impairment, DM, asthma, epilepsy, migraine, conditions aggravated by fluid retention, depression and thromboembolism (high doses); lactation.

Side Effects

>10% Headache (12%)
Acne (15%)
Ovarian cysts (13%)
Enlarged follicles (12%)
Amenorrhea (1-12%)
Abdominal pain (12%)
Uterine/vaginal bleeding alterations (52%)
Intermenstrual bleeding/spotting (23%)
Vulvovaginitis (20%)
Ectopic pregnancy (?50%) 1-10% Depression (4%)
Migraine (2%)
Alopecia (1%)
Dysmenorrhea (9%)
Menorrhagia (6%)
Breast tenderness (3-9%)
Pelvic pain (6%)
Leukorrhea (5%)
Vaginal discharge (4%)
Pelvic infection (1%) <1% Angioedema
Cervical perforation
Failed insertion
Sepsis
Uterine bleeding
Device breakage Potentially Fatal: Thrombocytopenia
stroke.

Contra indication

Pregnancy, undiagnosed vaginal bleeding, severe arterial disease; liver adenoma, porphyria; after recent evacuation of hydatidiform mole; history of breast cancer; hepatic impairment.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.